UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2014
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-51820 | | 77-0567768 |
| (State or other jurisdiction | | (Commission | | (IRS Employer |
| of incorporation) | | File Number) | | Identification No.) |
| | | | |
Alexza Pharmaceuticals, Inc. 2091 Stierlin Court Mountain View, California | | 94043 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 — Other Events
Item 8.01. Other Events.
On September 18, 2014, Alexza Pharmaceuticals, Inc., a Delaware corporation, issued a press release to provide an update on the commercial activities related to ADASUVE inhalation powder in the European Union. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
| | |
Exhibit Number | | Description |
| |
| 99.1 | | Press Release titled “Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities” dated September 18, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | ALEXZA PHARMACEUTICALS, INC. |
| Date: September 18, 2014 | | | | | | |
| | | | By: | | /s/ Mark Oki |
| | | | | | Mark Oki |
| | | | | | Senior Vice President, Finance, Chief Financial Officer and |
| | | | | | Secretary |
INDEX TO EXHIBITS
| | |
Exhibit Number | | Description |
| |
| 99.1 | | Press Release titled “Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities” dated September 18, 2014. |
